<SEC-DOCUMENT>0001193125-24-167412.txt : 20240625
<SEC-HEADER>0001193125-24-167412.hdr.sgml : 20240625
<ACCEPTANCE-DATETIME>20240625060628
ACCESSION NUMBER:		0001193125-24-167412
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240625
FILED AS OF DATE:		20240625
DATE AS OF CHANGE:		20240625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241066093

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d778726d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as June 25, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d778726dex991.htm">Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 25, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d778726dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g778726snap6.jpg" ALT="LOGO" STYLE="width:8.70208in;height:1.08542in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Signs Exclusive License Agreement with Cardiff University </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>for Next Generation <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-LAG-3</FONT></FONT> Molecules for Cancer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 25</B><B></B><B>&nbsp;June </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting
the Company exclusive rights to develop and commercialise <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT> small molecules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of promising compounds that block <FONT STYLE="white-space:nowrap">LAG-3,</FONT> an immune checkpoint known to reduce the immune system&#146;s
response to fight cancer, have been identified under Immutep&#146;s collaboration with the world-leading scientists at Cardiff University. Led by Professor Andrew Godkin of Cardiff University, Professor Andrea Brancale (now of the University of
Chemistry and Technology, Prague), and Dr Fr&eacute;d&eacute;ric Triebel, Immutep CSO, the compounds were identified by chemical library screening, molecular modelling (virtual screening) and synthetic chemistry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor Andrew Godkin of Cardiff University said:</B> &#147;Our collaboration with Immutep has been exciting and fruitful, resulting in a number of small
molecules with the potential to fight cancer by blocking the interaction between <FONT STYLE="white-space:nowrap">LAG-3</FONT> on T cells and MHC Class&nbsp;II on antigen-presenting cells. Small molecules represent the next generation of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT> therapies and hold tremendous promise, as they can be given to cancer patients as a convenient oral pill.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, over a dozen companies have initiated clinical trials investigating antagonist or &#147;blocking&#148; <FONT STYLE="white-space:nowrap">LAG-3</FONT>
antibodies including Bristol Myers Squibb&#146;s relatlimab, which was approved by the FDA in 2022 as part of a fixed dose combination with nivolumab for the treatment of metastatic melanoma. This new combination, known as Opdualag<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, achieved commercial sales of US$252&nbsp;million and US$627&nbsp;million in 2022 and 2023, respectively. Immutep&#146;s program aims to develop an orally-available small molecule <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT> treatment for cancer patients at a lower cost compared with the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT>
monoclonal and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are commercially available or under clinical development today. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, Immutep CSO, said:</B> &#147;With our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, eftilagimod alfa, entering late-stage clinical trials in oncology and IMP761, the world&#146;s first <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody
targeting the root cause of autoimmune diseases scheduled to enter the clinic by <FONT STYLE="white-space:nowrap">mid-year,</FONT> the team at Immutep continues to build on its pioneering leadership position in the
<FONT STYLE="white-space:nowrap">LAG-3</FONT> therapeutic landscape with this novel program. This License Agreement harnesses many years of collaborative work with the expert team at Cardiff University and enables us to advance the most promising
preclinical compounds towards the next stage of development.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A joint patent application has been filed by Immutep S.A.S. and University College
Cardiff Consultants Limited (a Cardiff University affiliate) to protect the new intellectual property. The License Agreement builds on Immutep&#146;s collaboration with Cardiff University which commenced in 2019. University College Cardiff
Consultants Limited will receive an upfront payment of &pound;25,000 and a milestone payment upon first commercial sale of a licensed product, and is eligible to receive low single-digit sales based royalties. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g778726snap6.jpg" ALT="LOGO" STYLE="width:8.70208in;height:1.08542in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiff University </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardiff University is recognised in independent government assessments as one of Britain&#146;s leading teaching and research universities and is a member of
the Russell Group of the UK&#146;s most research intensive universities. The 2021 Research Excellence Framework found 90% of the University&#146;s research to be word-leading or internationally excellent. Among its academic staff are two Nobel
Laureates, including the winner of the 2007 Nobel Prize for Medicine, Professor Sir Martin Evans. Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The
University&#146;s breadth of expertise encompasses: the College of Arts, Humanities and Social Sciences; the College of Biomedical and Life Sciences; and the College of Physical Sciences and Engineering. Its University institutes bring together
academics from a range of disciplines to tackle some of the challenges facing society, the economy, and the environment. More at <U>www.cardiff.ac.uk</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>c.strong@morrowsodali.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g778726snap6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g778726snap6.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( (<$  ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:]&SN\_I_2NJUCT4^EK)=1:-OD/;Y!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M"XCZU@Z=1+EE.*:7JD]SHAP![ ?I6J.E:)>0M PH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H \;T+X]?"WQ+XI3P;HGBNSO-=DEGM[>!;34T@O+FV#F
M:&SOI;)+2Y=5BF.$N#N\HB(R=@#V-3D ^O/^% "T % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H CDC$B.G0,C(2." P*D@CN 3CZT ?#'P\_8^OO!?Q%T?Q5<^+[2_T;P]JB
M:I86T6GW5OJ5W);%WLX;IA=&& +*8&F=?,\SR2$1!*]&P;'W4HP .!CTX H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MT\9:G9^%O'UI8:#JUV$@L-;M)9(M(U"\#+&+:[AN3G3+F0E2KB62%V8I^Z(
M)^@+3Y'VJ$C)R%'R_+G!' Y 'J.>U5S22M?3L#^%P^R]T.V*.V,>Y!_/-0TK
M6MHNA*C&+NE9K2_]>@!%7HH'T[4UHK;)="I>];FUY=A< >WZ4?H))1V5K"]/
MP_I0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * *=[_Q[W'_7M-_Z :%M+T_S,L1_N]7_  R_
M])9^7?PJ_P"2D>"O^QAT[_T>*^/PG^\Q_P"OOZL_(<H_Y'.%_P"PG]9'W%\?
M?^24^)/KI/\ Z?--KZ+,O]V?HOT/T7B3_D6XC_KU^J/GC]EK_D<M>_[%X_\
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M!>V,UG!.FHI;O-86_FWUK<0[;B9/("E 2_EJ#N89 /O1?V(/AL1QXF\; ?\
M7SX?] >WA^@!?^&'_AL!_P C/XW&01Q<Z!QD8X_XI\<C- 'J_C?PE8^!_P!G
MKQAX5TR>YN;#1/ &OV=O/>M"UU+&+*]EWS-;PQ1F3?+_  QH..E 'P)^Q^0O
MQIT@=,:#KW<#.=-V@#)'.5_E0!^NI(4>@_+&.Y]@!0!^/_[67B&TUSXT:Q%:
M,63P_9:9H3NH41_;;>V-W<C<'.5C>]DB8X!#JRXP-U'Z!^A^BO[.=A-IOP3^
M'MO,I5WT5KY5/:'4[^\U. CIP8;M"/KWZT >V4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M%OI=A9:9:1""ST^TMK&SA48$-K:0K;P1#U"QQJ >.,9&<Y +U !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M Y6^\=:^?A;\3/%%E?3V^H:!K7C2UT:XFTOR+JSL])U-K;3E;3KNRW^;'"I
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M9+/RKV$P/N6UT>"5I%CVX(D RO(/2C8-CZ4H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9_\ !^/_ )4T?VW_ -.U]P?Z[2_Y]+_P%?YA_P -8-_T)9_\'X_^5-']M_\
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M_#6#?]"6?_!^/_E31_;?_3M?<'^NTO\ GTO_  %?YA_PU@W_ $)9_P#!^/\
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M9_\ !^/_ )4T?VW_ -.U]P?Z[2_Y]+_P%?YA_P -8-_T)9_\'X_^5-']M_\
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M_#6#?]"6?_!^/_E31_;?_3M?<'^NTO\ GTO_  %?YA_PU@W_ $)9_P#!^/\
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M9_\ !^/_ )4T?VW_ -.U]P?Z[2_Y]+_P%?YA_P -8-_T)9_\'X_^5-']M_\
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M_#6#?]"6?_!^/_E31_;?_3M?<'^NTO\ GTO_  %?YA_PU@W_ $)9_P#!^/\
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M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\
M@JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I
M\ON_X ?ZEX?_ *#G_P""_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_
MJ7A_^@Y_^"_^ '_#*6F?]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""
M_P#@!_PREIG_ $.&H?\ @JMO_DRC^Q/^GR^[_@!_J7A_^@Y_^"_^ '_#*6F?
M]#AJ'_@JMO\ Y,H_L3_I\ON_X ?ZEX?_ *#G_P""_P#@"?\ #*6FC_F<+\X[
F?V5;#./^WRC^Q.77VJ:CTMV^0GP9ATO]\<K=.2U_*]M+[7Z'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
